Overview
Compare with Selecta Biosciences (United States), Can Fite Biopharma or MEDICINOVA INC, or pick any stock.
- TickerAAGH on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersAlhambra, California1
- Incorporated inCA2
- Business address1609 W Valley Blvd Unit 338A, Alhambra, Ca 918032
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Company set up a 100% owned subsidiary International Institute of Great Health, Inc. (IIGH) under the laws of the State of California.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue7¢$52.6K
- Selling, general and admin93¢$722.1K
Out of $391.7K in revenue.4 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| Sales | $391.7K | $294.7K |
| Cost of goods sold | $52.6K | $124.9K |
| Gross profit | $339.1K | $169.8K |
| Selling expense | $50.9K | $95.8K |
| General and administrative expense | $671.2K | $856.6K |
| Selling, general and administrative expenses | $722.1K | $952.5K |
| Loss from operations | -$382.9K | -$782.7K |
| Interest income | $46 | $61 |
| Interest expense | -$338.4K | -$443.7K |
| Other income (expenses) | -$338.3K | -$443.7K |
| Loss before income taxes | -$721.2K | -$1.2M |
| NET LOSS | -$721.2K | -$1.2M |
| BASIC LOSS PER SHARE (in Dollars per share) | $0.00 | $0.00 |
| DILUTED LOSS PER SHARE (in Dollars per share) | $0.00 | $0.00 |
| BASIC (in Shares) | 21.1B shares | 21.1B shares |
| DILUTED (in Shares) | 21.1B shares | 21.1B shares |
| Non-controlling interest share of loss | -$2.1K | -$5.8K |
| Net loss attributed to the owners of the Company | -$719.1K | -$1.2M |
| Foreign currency transaction | -$443 | $983 |
| Comprehensive loss | -$719.6K | -$1.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Cash | $44.1K | $54.9K | |
| Account receivable, net | $0 | $55.1K | |
| Inventory | $164.7K | $83.1K | |
| Prepaid and other assets | $28.0K | $32.3K | |
| TOTAL CURRENT ASSETS | $236.7K | $225.5K | |
| Right-of-use asset, net | $25.2K | $43.3K | |
| Other assets | $11.8K | $11.8K | |
| Property and equipment, net | $28.1K | $42.9K | |
| TOTAL ASSETS | $301.8K | $323.5K | |
| Accounts payable | $1.5M | $1.4M | |
| Tax payable | $3.8K | $1.7K | |
| Short term loan | $595.1K | $607.0K | |
| Other payable | $18.9K | $118.4K | |
| Wage and wage tax payable | $359.0K | $239.1K | |
| Due to related party | $1.3M | $1.1M | |
| Advances from customers | $78.0K | $59.6K | |
| Lease liability current | $25.2K | $21.7K | |
| TOTAL CURRENT LIABILITIES | $3.8M | $3.6M | |
| Lease liability non-current | $0 | $21.6K | |
| Long term loan | $2.2M | $1.8M | |
| Total Non-Current liabilities | $2.2M | $1.9M | |
| TOTAL LIABILITIES | $6.0M | $5.4M | |
| Commitments and Contingencies | $0 | $0 | |
| Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding | $0 | $0 | |
| Common stock, no par value, unlimited shares authorized; 21,152,711,608 and 21,136,888,326 shares issued and Outstanding | $0 | $0 | |
| Additional paid-in capital | $5.1M | $5.0M | |
| Treasury stock: 52,150,000 shares as of June 30, 2025 and 52,100,000 as of June 30, 2024 | $0 | $0 | |
| Accumulated other comprehensive income | -$1.0K | -$1.5K | |
| Accumulated deficit | -$10.8M | -$10.1M | |
| Total deficit attributable to owners of the Company | -$5.7M | -$5.0M | |
| Non-controlling interest | -$82.6K | -$80.5K | |
| TOTAL SHAREHOLDERS DEFICIT | -$5.7M | -$5.1M | -$4.2M |
| TOTAL LIABILITIES AND SHAREHOLDERS DEFICIT | $301.8K | $323.5K | |
| Series A voting preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Series A voting preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Redeemable, convertible preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, shares issued (in Shares) | 21.2B shares | 21.1B shares | |
| Common stock, shares outstanding (in Shares) | 21.2B shares | 21.1B shares | |
| Treasury stock, shares (in Shares) | 52.1M shares | 52.1M shares |
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Cash | $44.1K | $54.9K | |
| Account receivable, net | $0 | $55.1K | |
| Inventory | $164.7K | $83.1K | |
| Prepaid and other assets | $28.0K | $32.3K | |
| TOTAL CURRENT ASSETS | $236.7K | $225.5K | |
| Right-of-use asset, net | $25.2K | $43.3K | |
| Other assets | $11.8K | $11.8K | |
| Property and equipment, net | $28.1K | $42.9K | |
| TOTAL ASSETS | $301.8K | $323.5K | |
| Accounts payable | $1.5M | $1.4M | |
| Tax payable | $3.8K | $1.7K | |
| Short term loan | $595.1K | $607.0K | |
| Other payable | $18.9K | $118.4K | |
| Wage and wage tax payable | $359.0K | $239.1K | |
| Due to related party | $1.3M | $1.1M | |
| Advances from customers | $78.0K | $59.6K | |
| Lease liability current | $25.2K | $21.7K | |
| TOTAL CURRENT LIABILITIES | $3.8M | $3.6M | |
| Lease liability non-current | $0 | $21.6K | |
| Long term loan | $2.2M | $1.8M | |
| Total Non-Current liabilities | $2.2M | $1.9M | |
| TOTAL LIABILITIES | $6.0M | $5.4M | |
| Commitments and Contingencies | $0 | $0 | |
| Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding | $0 | $0 | |
| Common stock, no par value, unlimited shares authorized; 21,152,711,608 and 21,136,888,326 shares issued and Outstanding | $0 | $0 | |
| Additional paid-in capital | $5.1M | $5.0M | |
| Treasury stock: 52,150,000 shares as of June 30, 2025 and 52,100,000 as of June 30, 2024 | $0 | $0 | |
| Accumulated other comprehensive income | -$1.0K | -$1.5K | |
| Accumulated deficit | -$10.8M | -$10.1M | |
| Total deficit attributable to owners of the Company | -$5.7M | -$5.0M | |
| Non-controlling interest | -$82.6K | -$80.5K | |
| TOTAL SHAREHOLDERS DEFICIT | -$5.7M | -$5.1M | -$4.2M |
| TOTAL LIABILITIES AND SHAREHOLDERS DEFICIT | $301.8K | $323.5K | |
| Series A voting preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Series A voting preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Redeemable, convertible preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, shares issued (in Shares) | 21.2B shares | 21.1B shares | |
| Common stock, shares outstanding (in Shares) | 21.2B shares | 21.1B shares | |
| Treasury stock, shares (in Shares) | 52.1M shares | 52.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| Net loss | -$721.2K | -$1.2M |
| Depreciation | $14.8K | $14.8K |
| Original issue discount | $0 | $48.0K |
| Stock compensation | $0 | $123.6K |
| (Reversal)/Increase of inventory provision | -$400 | $9.4K |
| Payment of lease and rent | -$82.6K | -$80.4K |
| Right of use asset net | $18.1K | -$1.3K |
| Lease liabilities net | $5.2K | $47.2K |
| Account receivable net | $55.1K | -$55.1K |
| Prepaid expenses and other assets | $4.3K | -$15.3K |
| Inventory | -$81.1K | $15.8K |
| Accounts payable and accrued expense | $112.7K | $19.9K |
| Customer advances | $18.4K | -$8.7K |
| Accrued interest for short term loan | $60.1K | $117.8K |
| Accrued interest for long term loan | $241.1K | $261.8K |
| Tax payable | $2.2K | $800 |
| Other payable | -$99.5K | $90.8K |
| Wage and wage tax payable | $119.9K | $21.8K |
| Net cash used in operating activities from continuing operations | -$332.9K | -$615.6K |
| Net cash used in operating activities | -$332.9K | -$615.6K |
| Net cash used in investing activities | $0 | $0 |
| Proceeds from issuance of common stock | $102.1K | $115.0K |
| Proceeds of short term loan | $0 | $37.5K |
| Repayment of short term loan | -$10.8K | -$201.9K |
| Interest payment to short term loan | -$61.3K | -$73.4K |
| Proceeds of long term loan | $150.0K | $60.0K |
| Repayment of long term loan | $0 | -$10.0K |
| Interest payment to long term loan | $0 | -$3.0K |
| Advances from related party | $635.0K | $969.9K |
| Repayment to related party | -$493.6K | -$276.6K |
| Net cash provided by financing activities | $321.5K | $617.4K |
| Net (decrease) increase in cash | -$11.3K | $1.8K |
| Effect of foreign currency translation | $443 | -$983 |
| Interest paid | $61.3K | $76.4K |
| Taxes paid | $800 | $800 |
No quarter-by-quarter statement was filed.
What it owns
What America Great Health reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $45.8K4 Jun 30, 2025 | $31.0K4 Jun 30, 2024 | +47.6% |
| Property and equipment, net | $28.1K4 Jun 30, 2025 | $42.9K4 Jun 30, 2024 | −34.5% |
| Operating-lease assets (leased space) | $25.2K4 Jun 30, 2025 | $43.3K4 Jun 30, 2024 | −41.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $164.7K4 Jun 30, 2025 | $83.1K4 Jun 30, 2024 | +98.0% |
| Raw materials | $72.4K4 Jun 30, 2025 | $56.4K4 Jun 30, 2024 | +28.4% |
| Finished goods | $101.2K4 Jun 30, 2025 | $36.1K4 Jun 30, 2024 | +180.3% |
Properties, in its own words
The Company currently is leasing an office building property in Los Angeles County California. The Company has a month-to-month leases agreement with GKT, Alhambra, LP after the previous lease term of the office space expired on November 30, 2023. The current monthly rent including monthly management fee is $4,939.17.
The Company has entered into an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from June 1, 2024 to May 31, 2026, after the prior lease expired on May 31, 2024. The current monthly rent including monthly management fee is $1,940.40.
Item 2 of the 10-K filed Apr 10, 2026.3
Former names
Timeline
- Aug 24, 20268-K Other events10
- Sep 15, 20258-K Executive or director change11
- Oct 25, 20248-K Entered a material agreement12
- Oct 18, 20248-K Entered a material agreement13
- Oct 9, 20248-K Entered a material agreement14
- Oct 4, 20248-K Entered a material agreement15
- Oct 2, 20248-K Entered a material agreement16
- Sep 26, 20248-K Entered a material agreement17
- Sep 17, 20248-K Entered a material agreement18
- Sep 10, 20248-K Entered a material agreement19
- Sep 3, 20248-K Entered a material agreement20
- Oct 31, 20238-K Change of auditor21
Filings
69 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 28 major events, 17 other. The latest 20:
- Sep 25, 2026NT 10-K EDGAR
- Aug 24, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Jun 22, 202610-Q EDGAR
- Jun 4, 202610-Q EDGAR
- Apr 10, 202610-K EDGAR
- Sep 29, 2025NT 10-K EDGAR
- Sep 15, 20258-K EDGAR
- May 15, 202510-Q EDGAR
- Apr 14, 202510-Q EDGAR
- Mar 27, 202510-Q EDGAR
- Feb 25, 202510-K EDGAR
- Nov 15, 2024NT 10-Q EDGAR
- Oct 25, 20248-K EDGAR
- Oct 18, 20248-K EDGAR
- Oct 9, 20248-K EDGAR
- Oct 4, 20248-K EDGAR
- Oct 2, 20248-K EDGAR
- Sep 30, 2024NT 10-K EDGAR
- Sep 26, 20248-K EDGAR
The 69 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How America Great Health is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAmerica Great Health1
- CIK0001098009
- Employer ID (EIN)98-01786213
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inWyoming3
- Fiscal year endsJune 301
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1609 W Valley Blvd Unit 338A, Alhambra, CA 918031
- Phone(888) 988-13331
- Shares outstanding21,204,811,608 as of Aug 4, 20269
- Public float$0 as of Dec 31, 20244
- AuditorGreengrowth CPAs, Los Angeles, California PCAOB ID 6580; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceOct 29, 19991
- Filings196 in all: 8-K (57), 10-Q (43), NT 10-Q (18), 10-K (14), NT 10-K (12), 10QSB (8), 10-Q/A (7), UPLOAD (7)1
All 27 form types
10-K/A (4), 10KSB (3), 8-K/A (3), CORRESP (3), S-1/A (3), 10KSB/A (1), 10QSB/A (1), 10SB12G (1), 8-A12G (1), 8-K12G3 (1), 8-K12G3/A (1), EFFECT (1), NTN 10K (1), PRE 14C (1), PRER14C (1), REVOKED (1), S-1 (1), S-8 (1), SC 14F1 (1)
- Latest filingsAnnual report (10-K) Apr 10, 2026
Quarterly report (10-Q) Aug 6, 2026
Latest 8-K (8-K) Aug 24, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| None |
From the cover page of the 10-K filed Apr 10, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
Legal proceedings
No legal proceedings are threatened or pending against us or any of our officers or directors. Further, none of our officers, directors or affiliates are parties against us or have any material interests in actions that are averse to the Company’s interests.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGAROther events
- 11SEC EDGARExecutive or director change
- 12SEC EDGAREntered a material agreement
- 13SEC EDGAREntered a material agreement
- 14SEC EDGAREntered a material agreement
- 15SEC EDGAREntered a material agreement
- 16SEC EDGAREntered a material agreement
- 17SEC EDGAREntered a material agreement
- 18SEC EDGAREntered a material agreement
- 19SEC EDGAREntered a material agreement
- 20SEC EDGAREntered a material agreement
- 21SEC EDGARChange of auditor